My name is Adil Daud. I’m a medical oncologist. I work at the University of California, San Francisco, where I direct melanoma research and the melanoma program.
Archive | Health Professionals
Melanoma: Progression After Immunotherapy
Jeffrey S. Weber, MD, PhD: Let’s transition to the elephant in the room. We’ve heard great things about single-agent PD-1 [programmed cell death protein 1] blockade, ipilimumab-nivolumab, BRAF/MEK—multiple combinations, all frontline therapy.
Posted in Melanoma News, Health Professionals, Video Reports
Combination Therapy in Mutated Melanoma
The big impact of MEK inhibitors has been 2-fold. One is that it delays resistance, which you know, you have this additional blockade for cells that have somehow managed to live without BRAF.
Posted in Melanoma News, Health Professionals, Video Reports
Novel Agents for the Treatment of Melanoma
Jeffrey S. Weber, MD, PhD: There’s a whole raft of phase III trials that will come to mature—SD-101, CMP-001, the MASTERKEY-265—and then there’s the NKTR-nivolumab trial.
Posted in Melanoma News, Health Professionals, Video Reports
